Evidence map›Paper›PMID 7759131›Full record

ArticleImmunogenetics1995

DNase I hypersensitivity mapping and promoter polymorphism analysis of human C4.

A K Vaishnaw, R Hargreaves, R D Campbell, B J Morley, M J Walport

Abstract read
PubMed Publisher
In one paragraph

Article in Immunogenetics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

A K VaishnawDept. of Medicine, RPMS, Hammersmith Hospital, London, UK.
R Hargreaves
R D Campbell
B J Morley
M J Walport
Hammersmith Hospital · GBMRC Epidemiology Unit · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human complement component C4 is encoded by two structurally distinct loci in the major histocompatibility complex (MHC) class III region. The two isotypes, C4A and C4B, differ at only four residues in the C4d fragment, but C4 constitutes the most polymorphic of the complement components. It is not known, however, whether the regions involved in the regulation of C4 expression also display polymorphic variation. By using the technique of DNase I hypersensitivity mapping, we established that the only area of transcriptional activity for C4 in the hepatocyte cell line, HepG2, occurs approximately 500 base pairs upstream of the transcriptional start site. This region was found to be remarkably constant in sequence when analyzed in the context of differing MHC haplotypes including HLA B57, C4A6, C4B1, DR7, which has been correlated with reduced expression of the C4A isotype. Similarly, polymerase chain reaction followed by single-strand conformation polymorphism analysis failed to demonstrate any promoter polymorphisms in 103 individuals comprising 52 systemic lupus erythematosus patients and 51 healthy controls.

Indexed as

Major Histocompatibility ComplexPromoter Regions, GeneticBase SequenceComplement C4Deoxyribonuclease IDNA PrimersGene Expression RegulationHaplotypesHumansMolecular Sequence DataPolymorphism, GeneticPolymorphism, Single-Stranded ConformationalRNA, MessengerTranscription, GeneticComplement C4Deoxyribonuclease IDNA PrimersRNA, Messenger

Identifiers

PMID7759131
OpenAlexW2005686981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.